- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03362411
A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet
February 22, 2018 updated by: Bristol-Myers Squibb
Randomized, Open-Label Study to Assess the Relative Bioavailability of a Single 100-mg Dose of BMS-986205 in Healthy Participants When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube Compared to an Intact Tablet of Similar Dose
The purpose of this study is to evaluate the absorption of BMS-986205 into the bloodstream of healthy volunteers, when administered as an intact tablet taken orally, or as a crushed tablet taken orally with soft food, or as a crushed tablet suspension taken via a nasogastric (NG) tube.
Eligible participants will be randomly assigned to 1 of 4 treatment sequences and will receive a single dose of BMS-986205 twice during the course of the study.
Study Overview
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78744
- PPD Austin Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed written consent form.
- Healthy male and female participants (not of childbearing potential), determined by no clinically significant deviation from normal in medical history, physical examination, ECGs (electrocardiograms) and clinical laboratory determinations.
- Women participants must have documented proof they are not of childbearing potential.
- Males sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for duration of treatment with BMS-986205, and for a total of 110 days after the last dose of BMS-986205; and must be willing to refrain from sperm donation during this time. Azoospermic males are exempt from contraceptive requirements.
- Normal renal function at screening (Glomerula Filtration Rate ≥ 80 mL/min/1.73 m2).
- Body Mass Index (BMI) of 18.0 kg/m2 to 32.0 kg/m2 inclusive.
Exclusion Criteria:
- Women who are of childbearing potential or breastfeeding.
- Any significant acute or chronic illness.
- Active tuberculosis (TB) requiring treatment, documented latent TB within the previous 3 years, or evidence of a past TB infection without documented adequate therapy. All participants will be required to have a QuantiFERON -TB Gold test performed at screening.
- History of Glucose-6-Phosphate Dehydrogenase deficiency (G6PD) or any other congenital hemolytic anemias.
- History of cardiac arrhythmias and/or autonomic instability.
- History of pulmonary, renal or liver disease.
- History of Gilbert's Syndrome.
- Recent (within 6 months of study drug administration) history of smoking or current smokers, including use of electronic cigarettes or nicotine-containing products such as tobacco for chewing, nicotine patches, nicotine lozenges or nicotine gum.
- Participants with active, known or suspected autoimmune disease. Participants with vitiligo or psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger may enroll.
- Major surgery within 4 weeks of study drug administration.
Other protocol defined inclusion/exclusion criteria could apply.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BMS-986205 intact tablet orally then crushed tablet orally
Single, 100 mg dose
|
Single 100 mg dose on Day 1 and Day 15
|
Experimental: BMS-986205 crushed tablet orally, then intact tablet orally
Single, 100 mg dose
|
Single 100 mg dose on Day 1 and Day 15
|
Experimental: BMS-986205 intact tablet orally then suspension via NG tube
Single, 100 mg dose
|
Single 100 mg dose on Day 1 and Day 15
|
Experimental: BMS-986205 suspension via NG tube then intact tablet orally
Single, 100 mg dose
|
Single 100 mg dose on Day 1 and Day 15
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed plasma concentration (Cmax) of single 100 mg dose of BMS-986205 administered orally as crushed tablet on soft food compared to intact tablet administered orally.
Time Frame: Up to 22 days
|
Measured by plasma concentration.
|
Up to 22 days
|
Maximum observed plasma concentration (Cmax) of single 100 mg dose of BMS-986205 administered via nasogastric (NG) tube as crushed tablet suspension compared to intact tablet administered orally.
Time Frame: Up to 22 days
|
Measured by plasma concentration.
|
Up to 22 days
|
Area under the plasma concentration time curve from time zero to 168 hours after dosing (AUC[0-168]) of single 100 mg dose of BMS-986205 administered orally as crushed tablet on soft food compared to intact tablet administered orally.
Time Frame: Up to 22 days
|
Measured by plasma concentration.
|
Up to 22 days
|
Area under the plasma concentration time curve from time zero to 168 hours after dosing (AUC[0-168]) of single 100 mg dose of BMS-986205 administered via nasogastric (NG) tube as crushed tablet suspension compared to intact tablet administered orally.
Time Frame: Up to 22 days
|
Measured by plasma concentration.
|
Up to 22 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of non-serious Adverse Events (AEs).
Time Frame: Up to 22 days
|
Safety and tolerability as measured by incidence of non-serious AEs.
|
Up to 22 days
|
Incidence of Serious Adverse Events (SAEs).
Time Frame: Up to 22 days
|
Safety and tolerability as measured by incidence of SAEs.
|
Up to 22 days
|
Number of participants with clinical laboratory abnormalities.
Time Frame: Up to 22 days
|
Up to 22 days
|
|
Number of participants with vital sign abnormalities.
Time Frame: Up to 22 days
|
Up to 22 days
|
|
Number of participants with electrocardiogram (ECG) abnormalities.
Time Frame: Up to 22 days
|
Up to 22 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 9, 2017
Primary Completion (Actual)
February 1, 2018
Study Completion (Actual)
February 1, 2018
Study Registration Dates
First Submitted
November 30, 2017
First Submitted That Met QC Criteria
November 30, 2017
First Posted (Actual)
December 5, 2017
Study Record Updates
Last Update Posted (Actual)
February 23, 2018
Last Update Submitted That Met QC Criteria
February 22, 2018
Last Verified
February 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CA017-070
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on BMS-986205
-
Edward KimBristol-Myers Squibb; National Cancer Institute (NCI)TerminatedUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
Bristol-Myers SquibbCompletedHealthy VolunteersUnited States
-
Thomas Jefferson UniversityBristol-Myers SquibbActive, not recruitingLarynx | Squamous Cell Carcinoma | Lip | Oral Cavity Squamous Cell Carcinoma | PharynxUnited States
-
Bristol-Myers SquibbCompletedMelanoma | Skin CancerUnited States, Canada, Netherlands, Spain, Australia, Italy, Japan, Germany, Ireland, United Kingdom, Czechia, Switzerland, Poland, France, Greece, New Zealand
-
Northwestern UniversityNational Cancer Institute (NCI)Active, not recruiting
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompleted
-
PDL BioPharma, Inc.TerminatedUlcerative ColitisBelgium, France, United States, Italy, Australia, Czech Republic, Netherlands, Ireland, Norway, Canada, Austria, Germany, Hungary, Ukraine
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedAdvanced CancerUnited States, Israel, Australia, Austria, Canada, Italy